Study protocol for a multi-institutional, randomised, double-blinded, placebo-controlled phase III trial investigating additive efficacy of duloxetine for neuropathic cancer pain refractory to opioids and gabapentinoids: the DIRECT study

INTRODUCTION: Management of patients with cancer suffering from neuropathic pain refractory to opioids and gabapentinoids remains an important challenge. Duloxetine is one of the choices after first-line treatment fails. The efficacy of duloxetine has been reported in patients with non-cancer diseas...

Descripción completa

Detalles Bibliográficos
Autores principales: Matsuoka, Hiromichi, Ishiki, Hiroto, Iwase, Satoru, Koyama, Atsuko, Kawaguchi, Takashi, Kizawa, Yoshiyuki, Morita, Tatsuya, Matsuda, Yoshinobu, Miyaji, Tempei, Ariyoshi, Keisuke, Yamaguchi, Takuhiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2017
Materias:
Palliative Care
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5724096/
https://www.ncbi.nlm.nih.gov/pubmed/28851798
http://dx.doi.org/10.1136/bmjopen-2017-017280

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5724096/
https://www.ncbi.nlm.nih.gov/pubmed/28851798
http://dx.doi.org/10.1136/bmjopen-2017-017280

Ejemplares similares